Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data

Vaccine

Volumn 29, Issue 5, 2011, Pages 1053-1071

  Gidudu, J ^a   Sack, D A ^b   Pina, M ^c   Hudson, M J ^d   Kohl, K S ^a   Bishop, P ^e   Chatterjee, A ^f   Chiappini, E ^g   Compingbutra, A ^a   da Costa, C ^h   Fernandopulle, R ⁱ   Fischer, T K ^j   Haber, P ^a   Masana, W ^k   de Menezes, Martins R ^l   Kang, G ^m   Khuri Bulos, N ⁿ   Killion, L A ^o   Nair, C ^p   Poerschke, G ^q   Rath, B ^r   Salazar Lindo, E ^s   Setse, R ^b   Wenger, P ^t   Wong, V C N ^u   Zaman, K ^v   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Sanofi Pasteur MSD GmbH   (Germany)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^f Panacea Biotec Ltd   (India)

^g UNIVERSITY OF FLORENCE   (Italy)

^h GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

ⁱ UNIVERSITY OF COLOMBO   (Sri Lanka)

^j STATENS SERUM INSTITUT   (Denmark)

^k National Ministry of Health   (Argentina)

^l INSTITUTO OSWALDO CRUZ   (Brazil)

^m CHRISTIAN MEDICAL COLLEGE   (India)

ⁿ JORDAN UNIVERSITY HOSPITAL   (Jordan)

^o PFIZER INC   (United States)

^p GlaxoSmithKline Pharmaceuticals Ltd   (India)

^q MERCK RESEARCH LABORATORIES   (United States)

^r UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^s DS Consult   (Peru)

^t RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^u UNIVERSITY OF HONG KONG   (Hong Kong)

^v INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

more..

Author keywords

Adverse event; Case definition; Diarrhea; Guidelines; Immunization

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; DEHYDRATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG SAFETY; HUMAN; IMMUNIZATION; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; VOMITING;

DIARRHEA; HUMANS; IMMUNIZATION; VACCINES;

EID: 78751584989     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.065     Document Type: Article

References (97)

1. American Gastroenterological Association medical position statement Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1461-1463.
2. Fine K.D., Schiller L.R. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1464-1486.
3. King C.K., Glass R., Bresee J.S., Duggan C. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003, 52:1-16.
4. Thapar N., Sanderson I.R. Diarrhoea in children: an interface between developing and developed countries. Lancet 2004, 363:641-653.
5. Thielman N.M., Guerrant R.L. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004, 350:38-47.
6. The Council of International Organizations for Medical Sciences Reporting adverse drug reactions. Gastro-Intestinal Disorders (SOC 0600) 1998, p. 48.
7. United States of America, Centers for Disease Control and Prevention World Health Organization: Children's Initiative. Report p. Proceedings of the consensus workshop: rotavirus vaccines for immunization of children in developing countries 1997.
8. World Health Organization, UNICEF, Johns Hopkins Bloomberg School of Public Health, USAID Implementing the new recommendations on the clinical management of diarrhoea: Guidelines for policy makers and Programme managers. 2006. ISBN 9241594217 2008, Available on the world wide web at [last accessed 07.10.08]. http://www.who.int/child_adolescent_health/documents/9241594217/en/index.html.
9. WHO The treatment of Diarrhoea: A manual for physicians and other senior health workers. 4th Revision of document WHO/CDD/SER/80.2 2008, Available on the world wide web at [last accessed 20.11.08]. http://whqlibdoc.who.int/publications/2005/9241593180.pdf.
10. Henry F.J., Bartholomew R.K. Epidemiology and transmission of rotavirus infections and diarrhoea in St. Lucia, West Indies. W Indian Med J 1990, 39:205-212.
11. Long K.Z., Wood J.W., Vasquez Gariby E., Weiss K.M., Mathewson J.J., de la Cabada F.J., et al. Proportional hazards analysis of diarrhea due to enterotoxigenic Escherichia coli and breast feeding in a cohort of urban Mexican children. Am J Epidemiol 1994, 139:193-205.
12. Clemens J.D., Stanton B.F., Harris J.R., Charkaborty J., Sack D.A., Rao M.R., et al. Exclusion of clinically atypical or microbiologically mixed diarrhoeal episodes from outcome events in a field trial of oral cholera vaccines. Int J Epidemiol 1989, 18:440-445.
13. Rennels M.B., Glass R.I., Dennehy P.H., Bernestein D.I., Pichichero M.E., Zito E.T., et al. Safety and Efficacy of high-dose Rhesus-Human Reassortant Rotavirus vaccines-Report of the National Multi center Trial. Pediatrics 1996, 97:7-13.
14. Ruiz-Palacios G., Pérez-Schael I., Velázquez R., Abate H., Breuer T., Costa Clemens S., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
15. WHO Department of child and adolescent Health and development. The Treatment of diarrhea: a manual for physicians and other senior health workers. WHO/CAH/03.7 10/03 2003, http://whqlibdoc.who.int/hq/2003/WHO_FCH_CAH_03.7.pdf.
16. Figueroa-Quintanilla D., Salazar-Lindo E., Sack R.B., Leon-Barua R., Sarabia-Arce S., Campos-Sanchez M., et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. The N Eng J Med 1993, 328:1653-1658.
17. Zareba G. A new combination vaccine for measles, mumps, rubella and varicella. Drugs Today 2006, 42(5):321-329.
18. Ehrenkranz P., Lanata C.F., Penny M.E., Salazar-Lindo E., Glass R.I. Rotavirus diarrhea disease burden in Peru: the need for a rotavirus vaccine and its potential cost savings. Rev Panam Salud Publ 2001, 10:240-248.
19. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Eng J Med 2006, 354:23-33.
20. Makino S., Sasaki K., Nakayama T., Oka S., Urano T., Kimura M., et al. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Am J Dis Child 1990, 144:905-910.
21. Halperin A.S., Smith B., Russell M., Hasselback P., Guasparini R., Skowronski D., et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000, 18:1312-1319.
22. Joines R.W., Blatter M., Abraham B., Xie F., De Clercq N., Bbaine Y., et al. A prospective randomized comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havarix and Engerix-B) in adults. Vaccine 2001, 19:4710-4719.
23. Mills E., Gold R., Thipphawong J., Barreto L., Guasparini R., Meekison W., et al. Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus b conjugate vaccine administered to infants at two, four and six months of age. Vaccine 1998, 16:576-585.
24. Jones R.L., Froeschle J.E., Atmar R.L., Matthews J.S., Sanders R., Pardalos J., et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 2001, 19:4635-4643.
25. Pichichero M.E., Blatter M.M., Kennedy W.A., Hedrick J., Descamps D., Friedland L.R. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006, 117:1084-1093.
26. Mahalanabis D., Lopez A.L., Sur D., Deen J., Manna B., Kanungo S., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PloS ONE 2008, 3(June (6)):e2323.
27. Verdonck F., Joensuu J.J., Stuyven E., De Meyer J., Muilu M., Pirhonen M., et al. The polymeric stability of the Escherichia coli F4 (K88) fimbriae enhances its mucosal immunogenicity following oral immunization. Vaccine. 2008, 26(October (45)):5728-5735. [Epub 2008 Aug 3].
28. Demirjian A., Levy O. Novel vaccines: bridging research, development and production. Expert Rev Vaccines 2008 Nov, 7(9):1321-1324.
29. McKenzie R., Venkatesan M.M., Wolf M.K., Islam D., Grahek S., Jones A.M., et al. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 2008, 9(June (26)):3291-3296. [Epub 2008 Apr 16].
30. Kohl K.S., Gidudu J., Bonhoeffer J., Miles Braun M., Buettcher M., Chen R.T., et al. The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine 2007, 22:5671-5674.
31. Kotowaska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 21:583-590.
32. Corrêa N.B., Péret Filho L.A., Penna F.J., Lima F.M., Nicoli J.R. A randomized controlled trial of B. lactis and S. thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005, 39:385-389.
33. Badruddin S.H., Islam A., Hendrinks K.M., Bhutta Z.A., Shaikh S., Snyder J.D., et al. Dietary risk factors associated with acute and persistent diarrhoea in children in Karachi, Pakistan. Am J Clin Nutr 1991, 54:745-749.
34. Howie P.W., Stewart Forsyth J., Ogston S.A., Clark A., du V., Florey C. Protective effect of breast feeding against infection. Br Med J 1990, 300:11-16.
35. Maung U.K., Nyunt-Wai N., Khin M., Khin M.M., Toe T. Effect on clinical outcome of breast feeding during acute diarrhoea. Br Med J 1985, 290:587-589.
36. Mølbak K., Gottschau A., Aaby P., Højlyng N., Ingholt L., da Silva A.P. Prolonged breast feeding, diarrhoeal disease, and survival of children in Guinea-Bissau. Br Med J 1994, 308(6941):1403-1406.
37. Duffy L.C., Byers T.E., Riepenhoff-Talty M., La Scolea L.J., Zielezny M., Ogra P.L. The effects of infant feeding on rotavirus-induced gastroenteritis; a prospective study. Am J Public Health 1986, 76:259-263.
38. Clark H.F., Bernstein D.I., Dennehy P.H., Offit P., Pichichero M., Treanor J. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004, 144:184-190.
39. Riepenhoff-Talty M., Bogger-Goren S., Li P., Carmody P.J., Barret H.J., Ogra P.L. Development of serum and intestinal antibody response to Rotavirus after naturally acquired Rotavirus infection in man. J Med Virol 1981, 1081(8):215-222.
40. Flores J., Perez-Schael I., Gonzalez M., Garcia D., Mireya P., Daoud N. Protection against severe rotavirus diarrhea by rhesus rotavirus vaccine in Venezuela infants. Lancet 1987, 1:882-884.
41. National Cancer Institute Common toxicity criteria manual 1999, National Cancer Institute, Bethesda (MD).
42. Division Of Microbiology And Infectious Diseases (DMID), NIAID Pediatric toxicity tables and division of aids table for grading the severity of adult and pediatric adverse events December, 2004.
43. Colomba C., Saporito L., Giammanco G.M., De Grazia S., Ramirez S., Arista S., et al. Norovirus and gastroenteritis in hospitalized children, Italy. Emerg Infect Dis Emerg Infect Dis 2007, 13(9):1389-1391.
44. Ruuska T., Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990, 22(3):259-267.
45. Sack D.A., Tacket C.O., Cohen M.B., Sack R.B., Losonsky G.A., Shimko J., et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect Immun 1998, 66:1968-1972.
46. Nelson E.A.S., Tam J.S., Bresee J., Poon K.H., Ng C.H., Ip K.S., et al. Assessment of diarrhoea severity in different aetiological groups. J Ped Gastroenterol Nutr 2004, 39(Supplement 1):S260.
47. Cama R.I., Parashar U.D., Taylor D.N., Hickey T., Figueroa D., Ortega Y.R., et al. Enteropathogens and other factors associated with severe disease in children with acute watery diarrhea in Lima, Peru. J Infect Dis 1999, 179:1139-1144.
48. Parashar U.D., Gibson C.J., Bresee J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12(2):304-306.
49. Al-Mazrou Y.Y., Khan M.U., Aziz K.M.S., Farag M.K., Al-Jefry M. Role of social factors in the prevalence of diarrhoeal disease in under-five Saudi children. J Trop Pediatr 1995, 41(Suppl. 1):S45-S52.
50. Parashar U.D., Hummelman E.G., Bresse J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
51. Parashar U.D., Gibson C.J., Bresee J.S., Glass R.I. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006, 12:304-306.
52. Orenstein E.W., Fang Z.Y., Xu J., Liu C., Shen K., Qian Y., et al. The epidemiology and burden of rotavirus in China: a review of the literature from 1983 to 2005. Vaccine 2007, 25:406-413.
53. Bresee J.S., Glass R.I., Ivanoff B., Gentsch J.R. Current Status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 1999, 17:2207-2222.
54. Glass R.I., Parashar U.D., Bresee J.S., Turcios R., Fischer T.K., Widdowson M.-A., et al. Rotavirus vaccines: current prospects and future challenges. Lancet 2006, 368:323-332.
55. Rennels M.B., Glass R.I., Dennehy P.H., Bernstein D.I., Pichichero M.E., Zito E.T., et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the National Multicenter Trial: Unites States Rotavirus Vaccine Efficacy Group. Pediatrics 1996, 97:7-13.
56. McGeer A., Campbel B., Emori T.G., Hierholzer W.J., Jackson M., Nicolle L.E., et al. definitions of infection for surveillance in long-term care facilities. APIC 1996, 1-6.
57. Prato R., Lopalco P.L., Chironna M., Barbuti G., Germinario C., Quarto M. Norovirus gastroenteritis general outbreak associated with raw shellfish consumption in South Italy. BMC Infectious Diseases 2004, 4:37. 10.1186/1471-2334-4-37.
58. Guerrant R.L., Van Gilder T., Steiner T.S., Thielman N.M., Slutsker L., Tauxe R.V., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32:331-351.
59. WHO Persistent diarrhoea in children in developing countries: memorandum from WHO meeting. Bulletin of World Health Organization 1988, 66:706-717.
60. Division of Diarrhoeal and Acute Respiratory Disease Control The treatment of diarrhoea: a manual for physicians and other senior health workers 1995, World Health Organization, Geneva, p. 1-54 (WHO/CDR/95.3).
61. Centers for Disease Control and Prevention Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
62. American Gastroenterological Association Medical position paper statement Guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999, 116:1461-1463.
63. Michael F. Diarrheal diseases 1991, Elsevier Science Publishing Co., Inc., New York (NY), ISBN 0-444-01573-6.
64. Ericsson C.D., Dupont H.L., Steffen P.T. Diarrhea 2003, BC Decker Inc., Hamilton, Ontario, ISBN 1-55009-219-7.
65. Dupont H.L., Ericsson C.D. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993, 328:1821-1827.
66. Read N.W., Harford W.V., Schmulen A.C., Read M.G., Santa Ana C., Fordtran J.S. A clinical study of patients with fecal incontinence and diarrhea. Gastroenterology 1976, 76:747-756.
67. Goldbert L.D., Ditchek N.D. Chewing gum diarrhea. Am J Dig Dis 1978, 23:568.
68. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines for clinical safety assessment (E2a-e) 2008, Available on the world wide web [last accessed 09.02.08]. http://www.ich.org/.
69. Council for International Organizations of Medical Sciences (CIOMS) Reporting form for international reporting of adverse drug reactions 2008, Available on the world wide web [last accessed 09.02.08]. http://www.cioms.ch/frame_what_is_cioms.htm.
70. CDC Guidelines for maintaining and managing the vaccine cold chain. MMWR 2003, 52:1023-1025. Available on the world wide web at [last accessed 26.01.08]. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5242a6.htm.
71. CDC General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2003, 55(RR 15):1-48. Available on the world wide web at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm?s_cid=rr5515a1_e%0d%0a [last accessed 26.01.08].
72. World Health Organization Temperature monitors for vaccines and the cold chain 1999, World Health Organization, Geneva, Switzerland, publication no. WHO/V&B/99.15. Available at: http://www.who.int/vaccines-documents/DocsPDF/www9804.pdf.
73. CDC: Mortality and Morbidity Weekly Report (MMWR). QuickStats: Percentage of Adults Aged >25 Years with Limitation of Activity Caused by One or More Chronic Conditions, by Education Level and Sex-National Health Interview Survey, United States, 2006. June 6, 2008/57(22); 607.
74. Moher D., Schulz K.F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991. CONSORT Group (Consolidated Standards of Reporting Trials), Available on the world wide web at [last accessed 08.08.08]. http://www.consort-statement.org/Initiatives/complements.htm.
75. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999, 354:1896-1900. Available on the world wide web [last accessed 08.08.08]. http://www.consort-statement.org/Initiatives/complements.htm.
76. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012. Available at: [last accessed 08.08.08]. http://www.consort-statement.org/Initiatives/complements.htm.
77. Gidudu J., Kohl K.S., Halperin S., Hammer S.J., Heath P.T., Hennig R., et al. A local reaction at or near injection site: case definition and guidelines for collection, analysis, and prevention of immunization safety data. Vaccine 2008, 26:6800-6813.
78. Marcy S.M., Kohl K.S., Dagan R., Nalin D., Blum M., Connell Jones M., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22:551-556.
79. Bonhoeffer J., Menkes J., Gold M.S., de Souza-Brito G., Fisher M.C., Halsey N., et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22:557-562.
80. Bonhoeffer J., Vermeer P., Halperin S., Kempe A., Music S., Shindman J., et al. Persistent crying in infants and children as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004, 22:587-592.
81. Bines J.E., Kohl K.S., Forster J., Zanardi L.R., Davis R.L., Hansen J., et al. Acute intussusception in infants and children as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22:569-574.
82. Hjelt K., Grauballe P.C., Andersen L., Schiotz P.O., Howitz P., Krasilnikoff P.A., et al. Antibody response in serum and intestine in children up to six months after naturally acquired rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1986, 5:74-80.
83. Ronsmans C., Bennish M.L., Wierzba T. Diagnosis and management of dysentery by community health workers. Lancet 1998, 3:552-555.
84. Abba K., Sinfield R., Hart C.A., Garner P. Antimicrobial drugs for persistent diarrhea of unknown or non-specific cause in children under six in low and middle income countries; systematic review of randomized controlled trials. BMC Infectious Disease 2009, 9:24. Available on the world wide web at: http//www.biomedcentral.com/147-2334/9/24 [last accessed 30.04.09].
85. Baker E.H., Sandle G.I. Complications of laxative abuse. Ann Rev Med 1996, 47(February):127-134. doi: 10.1146/annurev.med.47.1.127.
86. Olson A.F. Outpatient management of electrolyte imbalances associated with anorexia nervosa and bulimia nervosa. J Infusion Nurs 2005, 28(2):118-122.
87. Zimmerer T., Böcker U., Wenz F., Singer M.V. Medical prevention and treatment of acute and chronic radiation induced enteritis - is there any proven therapy? A short Review. Z Gastroenterol 2008, 46:441-448. doi: 10.1055/s-2008-1027150.
88. Malinowski S.S. Nutritional and metabolic complications of bariatric surgery, bariatric surgery. Am J Med Sci 2006, 331(4):219-225.
89. Bryant S., Singer J. Management of toxic exposure in children. Emerg Med Clin North Am Feb 2003, 21(1):101-119.
90. Williams C.D. Kwashiorkor a nutritional disease of children associated with a maize diet. Lancet 1935, 2:1151-1152.
91. Levine M.M., Bergquist E.J., Nalin D.R., Waterman D.H., Hornick R.B., Young C.R., et al. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet 1978, 27(May):1119-11122.
92. CDC Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55(No. RR-12). http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5512a1.htm?s_cid=rr5512a1_e.
93. CDC Recommendations and reports. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009, 58(RR02):1-25.
94. FDA News Release: February 3, 2006: FDA approves new vaccine to prevent rotavirus gastroenteritis in infants 2006, http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094063.htm.
95. FDA News Release: February 3, 2008: FDA approves new vaccine to prevent gastroenteritis caused by rotavirus 2008, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116875.htm.
96. Givon-Lavi N., Greenberg D., Dagan R. Comparison between two severity scoring scales commonly used in the evaluation of rotavirus gastroenteritis in children. Vaccine 2008, 26(46):5798-5801.
97. WHO/IVB/08.16 Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease 2009, Available on the world wide web [last accessed 11.12.09]. http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.16_eng.pdf.